Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.72 |
| ▸ | HTR2A | P28223 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 4/20 | 0.61 |
| ▸ | HTR7 | P34969 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068818 | 0.90 | HTR6 (0.77) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3560702 | 0.90 | HTR6 (0.73) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL2197288 | 0.90 | HTR6 (0.80) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL15503471 | 0.90 | HTR6 (0.80) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3562663 | 0.89 | HTR6 (0.82) | HTR6HTR2AHTR1AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL4807140 | 0.89 | HTR6 (0.78) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3567631 | 0.87 | HTR6 (0.81) | HTR6HTR2AHTR1AHTR7DRD2 | |
| Hydrochloric Acid SCHEMBL2199517 | 0.86 | HTR6 (0.80) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL2200350 | 0.85 | HTR6 (0.66) | HTR6HTR2AHTR1AHTR7DRD2 | |
| SCHEMBL3132360 | 0.83 | HTR6 (1.00) | HTR6HTR2AHTR1AHTR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | claimed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | claimed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | claimed |
| CN-1315809-C | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2007-05-16 | — | — | CN | claimed |
| CN-1656075-A | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2005-08-17 | — | — | CN | claimed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | claimed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR3B, HTR4 | HTR6 1/4885HTR2A 9/4885HTR1A 4/4885 |
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | HTR6 111/4885HTR2A 124/4885HTR1A 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.